1. GSK Consumer Q4 net profit up 8 pc at Rs 175 cr

GSK Consumer Q4 net profit up 8 pc at Rs 175 cr

GlaxoSmithKline (GSK) Consumer Healthcare Ltd today reported a 8.42 per cent increase in standalone net profit at Rs 175.88 crore for the fourth quarter ended March 31.

By: | Published: May 12, 2017 3:12 PM
The fourth quarter has delivered positive results for the company. We continue to remain the market leader in Health Food Drinks category.

GlaxoSmithKline (GSK) Consumer Healthcare Ltd today reported a 8.42 per cent increase in standalone net profit at Rs 175.88 crore for the fourth quarter ended March 31.

The company had posted a net profit of Rs 162.22 crore for the corresponding period a year ago, GSK Consumer Healthcare said in a BSE filing. Total income from operations for the quarter under review stood at Rs 1,208.76 crore as against Rs 1,192.22 crore during the same period last fiscal, up 13.87 per cent.

“The fourth quarter has delivered positive results for the company. We continue to remain the market leader in Health Food Drinks category. Our access strategy, with re-launch of Rs. 5 pack of base Horlicks and Boost has enabled deep penetration and uptake. Our recently launched awareness campaign around micronutrient deficiency, based on a study that found that up to 9 in 10 children’s diets could be deficient in essential nutrients has been well received. We are confident that our high science based Horlicks portfolio will help address this,” says Manoj Kumar, Managing Director, GlaxoSmithKline Consumer Healthcare Limited.

For the entire fiscal, the company however reported a decline in net profit at Rs 656.67 crore as against Rs 687.28 crore in 2015-16 fiscal. Total income from operations for the financial year stood at Rs 4,421.09 crore compared to Rs 4,564.38 crore in the previous year.

GSK said that its board has recommended a dividend of Rs 70 per equity share of Rs 10 each for the 12-month period ended March 31, 2017. Shares of the company closed 1.93 per cent down at Rs 5,250.80 apiece on BSE.

  1. No Comments.

Go to Top